Workiva Announces Julie Iskow as Chief Executive Officer
22.2.2023 00:15:00 EET | Business Wire | Press release
Workiva Inc. (NYSE: WK), the company powering transparent reporting for a better world, announced today that Julie Iskow, current President and Chief Operating Officer, has been appointed to succeed Marty Vanderploeg as Chief Executive Officer, effective April 1, 2023. Vanderploeg is stepping down as CEO, but will remain with the company in the role of Non-Executive Chair of the Board of Directors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230221005356/en/
Workiva Inc. (NYSE: WK) Announces Julie Iskow as Chief Executive Officer (Photo: Business Wire)
Current Board Chair and prospective Lead Independent Director Dave Mulcahy said, “The Board is delighted to appoint Julie Iskow to Chief Executive. She is a strong, respected, and values-driven leader with an impressive and proven track record of delivering consistent high-quality performance through her relentless commitment to our customers and to our people. Julie has played an instrumental role in Workiva’s success over the last three years. She is an engineer, technologist, and strategic operator, whose innovation-first mindset has created a differentiated product offering and sustainable rigor around Workiva’s platform and solutions. The Board is confident in Julie’s ability to lead Workiva through its next stage of growth.”
Of her new role, Iskow said, “Workiva is one of the most relevant and innovative technology companies of our time. We have a transformative platform, unbridled potential, and an enduring foundation on which to build our future. I consider it a distinct privilege to succeed Marty and work with our incredibly talented team to move Workiva’s legacy forward into our next phase of growth and impact.”
Mulcahy said, “We would like to thank Marty for his steadfast leadership. During his tenure, he transformed Workiva into the leading multi-solution platform company for assured integrated business reporting, serving 5,600 customers across the globe. Marty has been an exceptional leader for Workiva, championing an employee culture of progress, product innovation, customer focus, and achieving strong shareholder value. We look forward to working with him in his expanded Board leadership role.”
“As a co-founder of Workiva, I have had the good fortune of working with a talented team for the past 15 years, five of those as CEO,” said Vanderploeg. “Now is the right time for me, and for Workiva, to make this change. Since day one of Julie’s arrival, she’s made our organization better. Julie has spent the past three years thoughtfully building and shaping our remarkable leadership team and operational strategy as we progress toward a long-term goal of $1 billion in revenue. I look forward to supporting her in my new role as Non-Executive Chair.”
About Julie Iskow
Julie Iskow joined Workiva in 2019 as EVP and Chief Operating Officer. She has extensive experience scaling enterprise SaaS companies with strong, profitable growth and has a robust background in product development and optimizing operations. Iskow was promoted to President and Chief Operating Officer in March 2022 and has been overseeing day-to-day operations with global responsibility for technology, product, sales, partners, marketing, services, and customer and partner experience. This transition allows her and the Workiva team to continue with their excellence in execution.
Before joining Workiva, Iskow served as EVP and Chief Technology Officer at Medidata Solutions, creator of cutting-edge SaaS technology and analytics solutions for life sciences. Prior to Medidata, she was the Senior Vice President of Product Development and Chief Information Officer at WageWorks, a SaaS platform for consumer directed benefits solutions. Before WageWorks, she spent over a decade in engineering and technology leadership positions, responsible for automation and robotics software used in high-tech manufacturing.
She currently serves on the board of directors of Workiva Inc. and Five9, a leading provider of cloud software for contact centers. She has a bachelor of science degree from the University of California, Berkeley and a master of science degree from the University of California, Davis.
About Workiva
Workiva Inc. (NYSE:WK) is on a mission to power transparent reporting for a better world. We build and deliver the world’s leading cloud platform for assured integrated reporting to meet stakeholder demands for action, transparency, and disclosure of financial and non-financial data. Workiva offers the only unified SaaS platform that brings customers’ financial reporting, Environmental, Social, and Governance (ESG), and Governance, Risk, and Compliance (GRC) together in a controlled, secure, audit-ready platform. Our platform simplifies the most complex reporting and disclosure challenges by streamlining processes, connecting data and teams, and ensuring consistency. Learn more at workiva.com.
Follow Workiva on LinkedIn: www.linkedin.com/company/workiva
Like Workiva on Facebook: www.facebook.com/workiva
Follow Workiva on Twitter: www.twitter.com/workiva
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230221005356/en/
Contact information
Investor Inquiries:
Mike Rost
investor@workiva.com
(515) 663-4493
Media Inquiries:
Darcie Brossart
press@workiva.com
(515) 663-4471
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom